Home MarketAlembic Pharmaceuticals Ltd.

Alembic Pharmaceuticals Ltd. Stock Info: As on 2017-09-22 15:59:10

Nse

489.95

-10.40(-2.08%)
Change%
52 Week Range
469.85
15.00
699.00
5.00
Open501.00
Day's Range400.28 - 600.42
Value Traded (in ₹ Cr.) 1.45

Bse

489.65

-10.70(-2.14%)
Change %
52 Week Range
469.75
20.00
709.30
23.00
Open502.10
Day's Range400.28 - 600.42
Value Traded (in ₹ Cr.) 0.33

Stock Exchange

Category No. Of Shares Share %
ForeignPromoters 0.00 0.00%
IndianPromoters 137,007,545.00 72.68%
Mutual Funds/UTI 5,306,968.00 2.82%
FII 20,005,997.00 10.61%
Employee 0.00 0.00%
Public 21,539,930.00 11.43%
Government 0.00 0.00%
Others 4,064,051.00 2.16%
More

Key Statistics

Valuation Measures
Market Cap / Sales Ratio 3.78
Basic EPS (Rs.) 37.03
Cash EPS 40.85
BVPerShare Excl 81.17
Operating Revenue 158.70
PBDITPerShare 52.38
Dividend 0.00
NPPerShare 37.03
Current Ratio 2.31
Quick Ratio 1.37
PriceToBV 7.40
Earnings 0.06
PBDIT Margin 33.00
PBT Margin 30.52
NP Margin 23.33
Return On Assets 31.89
Retention Ratios 0.00
Parameter Mar-16 (₹ Cr.) Yoy%change
Total Income 2,997.26
Total Expenses 2,083.95
EBITDA 987.54
PBT 913.31
PAT 698.14
Net Income 698.14
More
Parameter Mar-16 (₹ Cr.) 6M % change
Total Income 1,491.44
Total Expenses 997.94
EBITDA 447.78
PBT 492.02
PAT 369.15
Net Income 0.00
More
Total Assets
Total Assets
Parameter Mar-16 (₹ Cr.) Yoy%change
Total share capital 37.70
Net worth 1,530.28
Investments 37.46
Total Liability 2,189.11
Total debt 0.00
Net block 789.59
Total Assets 2,189.11
Parameter Mar-16 (₹ Cr.) 6M % change
Total share capital 37.70
Net worth 1,530.28
Investments 37.46
Total Liability 2,189.11
Total debt 0.00
Net block 789.59
Total Assets 2,189.11
Company Curr Price Prev. Close Change% W's Low/High

Aarti Drugs Ltd.

526.85 535.6 -1.63
526544.45

Abbott India Ltd.

4252.9 4252.25 0.02
40014264

Ajanta Pharma Ltd.

1208.5 1256.6 -3.83
11881265

Albert David Ltd.

287.8 292.5 -1.61
282.5300.9

Alembic Ltd.

40.2 43.1 -6.73
38.1544.7

Alkem Laboratories Ltd.

1800.95 1801.2 -0.01
17341819

Alpa Laboratories Ltd.

31.7 30.2 4.97
27.8530.2
Company Curr Price Prev. Close Change% W's Low/High

Aarey Drugs & Pharmaceuticals Ltd.

103.15 101.05 2.08
90121.9

Aarti Drugs Ltd.

524.5 533.85 -1.75
525540

Aayush Food & Herbs Ltd.

48.55 48.55 0
48.5548.55

Abbott India Ltd.

4164 4269.8 -2.48
40354275

ABL Bio-Technologies Ltd.

0.81 0.78 3.85
0.750.81

Addlife Pharma Ltd.

0.46 0 0
0.460.5

Adinath Bio-Labs Ltd.

0.3 0.31 -3.23
0.30.3
More
Parameter Mar-16(in ₹ Cr.)
Cash from operating activities 847.53
Cash from investing activities -293.07
Cash from financing activities -274.05
Net change in cash 280.41

Stock Held By Mutual Fund Schemes

Scheme Holding (%)
ICICI Prudential Long Term Equity Fund 1.96%
ICICI Prudential Multicap Fund 2.00%
ICICI Prudential Balanced Fund 0.18%
ICICI Prudential Balanced Advantage Fund 0.15%
DSP BlackRock Small And Mid Cap Fund 0.43%
ICICI Prudential Child Care Plan - Gift Plan 3.97%

SAIL eyes higher market share on surging steel demand: Chairman

Armed with latest technologies and higher product mix, SAIL aims to tap big into the steel demand in India, which is projected to become the fifth- largest economy this year, its Chairman P K Singh said. Addressing the 45th annual general meeting of the state- owned Steel Authority of India Ltd (SAIL) here, Singh said the steel demand in India will witness a significant growth in future, given the current stage of development in Indian economy. The World Steel Association, in its short range outlook, has forecast 6.1 per cent growth in steel consumption for India in 2017, the SAIL chief added. According to Singh, the domestic steel demand is improving on the back of government policies and developmental goals, and SAIL is expeditiously equipping itself to serve market requirements fully and claim a broader market share. SAIL with newer and better technologies at its disposal aims to leverage potential of growth in steel demand by operating at rated capacities, product differentiation and customer satisfaction, Singh said. The chairman also shared the company's efforts towards product value addition. SAIL has done significant value addition in its product mix, with higher grades of steel... from Rourkela Steel Plant's new plate mill for the oil and gas sector, SAIL HT-600 for the automotive sector and high strength LPG steel grade from Bokaro Steel Plant, etc, Singh said. At Bhilai Steel Plant (BSP), the world's longest single piece rail of 130 metres is being produced and supplies of welded 260 metres rail panels to the Indian Railways are in progress. Besides, a 3 mtpa hot strip mill in Rourkela is slated to be installed by 2018. He further said, World economic recovery is on track... and presents a healthy sign for industrial and manufacturing activities across globe. India is projected to become the world's fifth-largest economy in 2017, surpassing UK and France and the world's third largest economy by 2023, surpassing Japan and Germany. Such kind of growth will definitely create larger steel demand and boost consumption in country, the chairman added. Listing out the achievements of SAIL, Singh said the company since inception has produced 475 million tonnes (mt) of crude steel and partnered in all major national projects requiring steel. The company is also taking initiatives towards remodelling its operations.

22-09-2017 16:49

PNB plans to raise up to Rs 5000 cr from markets

Punjab National Bank today said it plans to raise up to Rs 5,000 crore equity capital from the markets to fund growth. The public sector bank however did not give any indication as to whether it would be raised by diluting government equity or issuing Additional Tier-1 (AT1) bonds. The decision in this regard would be taken in the board meeting on September 27, PNB said in a filing to the stock exchanges. The bank would consider raising common equity Tier capital up to Rs 5,000 crore as per Basel III requirements, it said. PNB had reported over 12 per cent rise in net profit at Rs 343.40 crore for the quarter ended June 30, 2017. Total income of the bank rose to Rs 14,468.14 crore in the said quarter from Rs 13,475.41 crore a year ago. With regard to assets metrics, the bank's gross non- performing assets (NPAs) declined marginally to 13.66 per cent of gross advances as on June 30, 2017 from 13.75 per cent a year ago. Meanwhile, shares of the Bank closed trading at Rs 137.80 apiece, down 2.92 per cent from the previous close on BSE.

22-09-2017 15:47

SBI's new index at LSE to help investors track Indian bonds

State Bank of India, in partnership with FTSE Russell, brought out a new index series at the London Stock Exchange to enable investors and market participants to track Indian bond movement. FTSE Russell is a global data and analytics provider. The FTSE SBI Bond Index Series demonstrates SBI's commitment to play befitting leadership role in development of India's bond market, State Bank of India (SBI) said in a statement. We have teamed up with FTSE Russell to launch the FTSE- SBI Bond Index Series. This index will act as a key benchmark for Indian debt for foreign investors looking to invest in Indian debt market, SBI Chairman Arundhati Bhattacharya said in the statement. It will significantly contribute to development and broadening of the Indian bond market, Bhattacharya hoped. The index series, SBI said, provides the global investor community and other market participants the tools they need to analyse India's bond market. The launch follows the November 2015 visit of Prime Minister Narendra Modi in the UK when a letter of intent was singed between SBI and FTSE to jointly develop the new index tracking Indian fixed income securities. This initiative was also announced as a priority under the India UK Financial Partnership (IUKFP), SBI said further. Today's launch of this innovative index series demonstrates SBI's commitment to play befitting leadership role in development of India's bond market. This index is also an important enabler of India-focused funds and is expected to facilitate investment flows, the bank said. Meanwhile, shares of the Bank closed trading at Rs 261.90 apiece, down 2.46 per cent from the previous close on BSE.

22-09-2017 15:44

Adhunik Industries hits 52 week low on SAT order

Shares of Adhunik Industries plunged 20 per cent, hitting 52-week low, on the Bombay Stock Exchange after the Securities Appellate Tribunal (SAT) directed the market regulator to reverse their decisions all dated August 7, 2017 qua the appellant forthwith. According to data available with exchange, as much as 792 lakh shares changed hands over-the-counter as compared to two week average of 1.54 lakhs. Weighed down by the development, shares of the company declined as much as 20 per cent to hit 52-week low of Rs 83.55 apiece on the Bombay Stock Exchange. The stocks were currently trading at Rs 83.55 against previous close price of Rs 104.40. In a similar fashion, shares of the company were trading 19.98 per cent lower at Rs 79.10 apiece on the National Stock Exchange. Meanwhile, the broader benchmark BSE Sensex was trading at 31,944.47, down 425.57 points, or 1.30 per cent, at 14:45 hours.

22-09-2017 14:57

Dabur India joins hand with Amazon for ayurveda marketplace

Homegrown FMCG major Dabur India today said it has tied up with e-commerce major Amazon for an online ayurveda marketplace which will house all ayurvedic brands and products available in the country. The company, which will also offer consumers an insight into various ayurvedic medicines for treating a variety of ailments, said the idea is to service all health and personal care related needs of patients. The exclusive ayurveda e-marketplace has been hosted by Amazon India and the content is developed by Dabur India, the company said in a statement. Consumers can search basis companies, brands and ailments and will gain access to all ayurveda solutions available in the country today, Dabur India Executive Director Consumer Care Business KK Chutani said. Products of other ayurvedic manufacturing companies like Baba Ramdev-promoted Patanjali and Himalaya would also feature on the marketplace. By providing A+ content for developing this marketplace, Dabur also gains prime visibility on the portal, Chutani said. Meanwhile, shares of the company were trading at Rs 305.70 apiece, down 1.51 per cent from the previous close at 14:50 hours on BSE.

22-09-2017 14:48

Alembic Pharmaceutic - Updates

Alembic Pharmaceuticals Limited has informed the Exchange regarding ''Alembic Pharmaceuticals Limited receives EU GMP Certificate for its Formulation Facility at Panelav ''.

31-Aug-2017 06:07 PM

Alembic Pharmaceutic - Updates

With reference to the captioned matter, we would like to inform the exchange that the
Company has received EU GMP Certificate for the audit conducted at its Formulation Facility at Panelav from 8th August, 2017 to 10th August, 2017.

31-Aug-2017 05:51 PM

Alembic Pharma sells formulations manufacturing plant at Baddi

Alembic Pharmaceuticals said that it has sold its formulations manufacturing facility at Baddi. The company has sold its formulations manufacturing facility at Baddi on slump sale basis to Scott Edil Pharmacia (SEPL), a company engaged in the business of pharmaceuticals products. SEPL does not belong to the promoter / promoter group / group companies and is not related party of the company. The turnover and networth of the said manufacturing facility for the last financial year vis-a-vis turnover and networth of the company is insignificant. The company continues to meet its domestic formulation demand from Sikkim unit and international formulation demand from its Panelav unit. Meanwhile, shares of the company were trading at Rs 515 apiece, up 1.85 per cent from the previous close at 10:50 hours on BSE.

24-Aug-2017 10:53 AM

Alembic Pharmaceutic - Updates

Alembic Pharmaceuticals Limited has informed the Exchange regarding ''Intimation for sale of Baddi Undertaking''.

23-Aug-2017 07:05 PM

Alembic Pharmaceutic - Updates

Sub: Intimation for Sale of Baddi Undertaking

With reference to the captioned matter, we would like to inform the exchange that the Company has today sold on slump sale basis its formulations manufacturing facility at Baddi, Dist. Solan (H.P) to Scott Edil Pharmacia Limited ('SEPL'), a company engaged in the business of pharmaceuticals products.

SEPL does not belong to the promoter / promoter group / group companies and is not related party of the Company.
The turnover and networth of the said manufacturing facility for the last financial year vis--vis turnover and networth of the Company is insignificant.
The Company continues to meet its domestic formulation demand from Sikkim Unit and international formulation demand from its Panelav Unit.
We request you to kindly take the same on record.

23-Aug-2017 06:41 PM

Alembic Pharmaceutic - Updates

With reference to the captioned matter, we would like to inform the exchange that the
Company has received EU GMP Certificate for the audit conducted at its Formulation Facility at Panelav from 8th August, 2017 to 10th August, 2017.

31-Aug-2017 05:51 PM

Alembic Pharmaceutic - Updates

Sub: Intimation for Sale of Baddi Undertaking

With reference to the captioned matter, we would like to inform the exchange that the Company has today sold on slump sale basis its formulations manufacturing facility at Baddi, Dist. Solan (H.P) to Scott Edil Pharmacia Limited ('SEPL'), a company engaged in the business of pharmaceuticals products.

SEPL does not belong to the promoter / promoter group / group companies and is not related party of the Company.
The turnover and networth of the said manufacturing facility for the last financial year vis--vis turnover and networth of the Company is insignificant.
The Company continues to meet its domestic formulation demand from Sikkim Unit and international formulation demand from its Panelav Unit.
We request you to kindly take the same on record.

23-Aug-2017 06:41 PM

Alembic Pharmaceutic - Updates

Subject: Disruption in plant operations at Algerian JV

This is to inform the exchange that there was a fire incident at our Algerian Joint Venture plant at Constantine, Algeria Constantine, Algeria. It has had been brought under control. No casualties or injury to any persons is reported. The cause of accident and the extent of damage is being investigated and assessed. Though the fixed assets and inventories are covered under insurance policies and we do not expect a major adverse impact, we expect a disruption in operations till the plant is put back on stream.

Alembic Mami SPA is a joint venture in which 49% equity stake is held by Alembic Global Holding SA (AGH), 100% subsidiary of Alembic Pharmaceuticals Limited.

We request you to kindly take the same on record.

18-Aug-2017 04:56 PM

Corporate Details

About Management

2011 Alembic Pharmaceuticals Limited ( the Resulting C ompany ) was originally incorporated on 16th June, 2010 in the name and style 'Alembic Pharma Limited', under the Companies Act, 1956 and had received the Certificate of Commencement of business on 1st July, 2010. The company changed its name from Alembic Pharma Limited to Alembic Pharmaceuticals Limited and the Registrar of Companies, Gujarat has approved the change of name and issued a fresh certificate of incorporation consequent upon change of name on 12th March, 2011. 2012 Alembic and Breckenridge Announce Paragraph IV ANDA Litigation with Pfizer on Desvenlafaxine (Pristiqr). Alembic Pharmaceuticals Limited enters into a product development and license agreement with Accu-Break Pharmaceuticals, Inc, USA. 2013 -Alembic gets USFDA approval for its NDA - Desvenlafaxine Base Extended Release Tablets and also entered into an out-licensing agreement with Ranbaxy Pharmaceuticals Inc (Ranbaxy) to market its product in USA. 2014 -"Alembic announces joint venture with Adwiya Mami SARL Algeria through its wholly owned Subsidiary - Alembic Global Holding S.A.". 2015 -Alembic Pharmaceuticals Ltd. arm signs exclusive agreement with Novartis 2016 - Alembic Pharma inks JV agreement with Orbicular Pharma

Registered Office

Samardung Busty, Namthang,

,,,      ,

Registrar Details

Link Intime India Pvt. Ltd.